Details of Drug-Drug Interaction
| Drug General Information (ID: DDI7XZSP42) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Talimogene laherparepvec | Drug Info | Tafasitamab | Drug Info | |||||
| Drug Type | Vaccine | Monoclonal antibody | |||||||
| Therapeutic Class | Anticancer Agents | Antineoplastics/Cd19 Monoclonal Antibodies | |||||||
| Mechanism of Talimogene laherparepvec-Tafasitamab Interaction (Severity Level: Major) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Antagonize the effect of vaccine/toxoid Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Talimogene laherparepvec | Tafasitamab | |||||||
| Mechanism | Immunomodulatory infective agent | Immunosuppressive effects | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Vaccine/toxoid | ||||||||
| Factor Description | The beneficial effects of the vaccine/toxinoid may be reduced, leading to a diminished or suboptimal immune response. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Talimogene laherparepvec should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Treatment with talimogene laherparepvec may need to be deferred until after such therapy is discontinued and the patient's immune system has sufficiently recovered. | ||||||||
| References | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Product Information. Imlygic (talimogene laherparepvec). Amgen USA, Thousand Oaks, CA. | ||||||||||||||||||